Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
SyntheticMR AB (publ) ("SyntheticMR") announced today that leading executives (CEO and Head of US region) agreed on the purchase of a total of 300 000 call options. The options are issued by SyntheticMR's principal shareholders (Nortal Investments AB, managed by Staffan Persson), founder (Marcel Warntjes) and Chairman of the Board (Johan Sedihn), which means there is no dilution for other shareholders. Holders have the right to acquire one (1) share in SyntheticMR for each call option.
The duration of the incentive program is almost 5 years and exercising the call options can take place between June 2023 and June 2026. The exercise price per share shall amount to SEK 50. The price of the call option has been set at SEK 15 and has been calculated using Black & Scholes' valuation model.
As of today the issuers of the options own a total of 17 206 890 shares in SyntheticMR, equivalent of 42,6 percent of the shares and votes.
This disclosure contains information that SyntheticMR AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 27-08-2021 08:16 CET.